• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Immunol . Nationwide Survey of Multisystem Inflammatory Syndrome in Children Associated with Coronavirus Disease 2019 in Japan

tetano

Editor, Senior Moderator
J Clin Immunol


. 2024 Nov 30;45(1):51.
doi: 10.1007/s10875-024-01845-z. Nationwide Survey of Multisystem Inflammatory Syndrome in Children Associated with Coronavirus Disease 2019 in Japan

Daisuke Matsubara[SUP] #[/SUP][SUP] 1 [/SUP], Yuri Matsubara[SUP] #[/SUP][SUP] 2 [/SUP], Mamoru Ayusawa[SUP] 3 [/SUP], Hiromichi Hamada[SUP] 4 [/SUP], Mitsuru Seki[SUP] 5 [/SUP], Hiroyuki Yamagishi[SUP] 6 [/SUP], Yoshihide Mitani[SUP] 7 [/SUP], Yoshihiro Onouchi[SUP] 8 [/SUP], Hiroyuki Moriuchi[SUP] 9 [/SUP], Isao Miyairi[SUP] 10 [/SUP], Keiko Tanaka-Taya[SUP] 11 [/SUP], Tomohiro Katsuta[SUP] 12 [/SUP], Hiroshi Kurosawa[SUP] 13 [/SUP], Kazunori Aoki[SUP] 13 [/SUP], Naoki Shimizu[SUP] 12 [/SUP], Yosikazu Nakamura[SUP] 14 [/SUP]



Affiliations
Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) presents some clinical overlap with Kawasaki disease (KD). Although KD is common in Japan, the clinical characteristics of MIS-C in Japan remain unknown. Therefore, we aimed to determine the epidemiological and clinical features of MIS-C in Japan.
Methods: Using a case reporting form, a nationwide registry was created between November 2020 and March 2023, involving 2,080 facilities throughout Japan. We prospectively and retrospectively enrolled patients with MIS-C. The primary outcomes were the number and incidence rates of children with MIS-C. The secondary outcomes included clinical features, such as KD phenotype, organ involvement, shock, intensive care unit admission, and coronary artery lesions.
Results: Among 398 patients registered, central review identified 129 MIS-C cases (mean age: 8·8 ± 3·7 years). The overall incidence rate was estimated to be 1·5 per 100,000 COVID-19 cases, exhibiting a decline as the COVID-19 pandemic progressed, from 12·3 cases (Pre-Delta) to 1·3 cases (Omicron); 80% of MIS-C cases occurred during the Omicron variant predominant period, and 72% of children with MIS-C met the KD criteria. Cardiovascular (88%) and gastrointestinal (90%) involvement were frequent. In Japan, MIS-C cases showed comparatively less severe clinical features, with shock in 29% and admission to the intensive care unit in 12% of cases. Coronary artery lesions were identified in 15 cases (11·6%), irrespective of the presence of shock. No fatalities were reported.
Conclusion: The incidence of MIS-C was low in Japan. The clinical features distinctively exhibited a more KD-like phenotype, with less severe clinical features.

Keywords: COVID-19; Kawasaki disease; incidence; multisystem inflammatory syndrome in children.

 
Back
Top Bottom